Jura Bio Files IPO Prospectus: Pioneering AI and Synthetic Biology Platform with a 100-Billion-Strong Human TCR Library for Next-Generation Immunotherapies

The integration of artificial intelligence and synthetic biology has brought revolutionary advantages to the biotechnology field. This interdisciplinary fusion not only accelerates the discovery of new biomolecules and therapeutic targets but also enhances the precision of experimental design and the efficiency of drug development. The combination of AI's powerful data processing capabilities with the innovative design of synthetic biology enables the formulation of personalized medical solutions, the simulation and prediction of complex biological systems, and the optimization of bio-manufacturing processes.

In the pharmaceutical field, AI + synthetic biology has greatly improved the efficiency of drug development and treatment precision by accelerating new drug discovery, optimizing drug design, enabling personalized medicine, and improving the efficiency of clinical trials. This technological integration not only speeds up the market entry of new therapies and reduces costs but also provides new strategies for treating complex diseases, with the potential to continue bringing more innovative and effective medical solutions to patients in the future.

This interdisciplinary integration has become a hot spot in the pharmaceutical track, not only accelerating the discovery of new biomolecules and therapeutic targets but also improving the precision of experimental design and the efficiency of drug development. Jura Bio is at the forefront of this innovative wave, leveraging the powerful data processing capabilities of AI and the innovative design of synthetic biology to pave new paths for personalized medicine, simulation and prediction of complex biological systems, and optimization of biomanufacturing processes.

Jura Bio, founded in 2017, is dedicated to developing an advanced technology platform that combines generative machine learning and synthetic biology, focusing on the discovery and development of genetic medicines.Jura Bio was co-founded by leading scientists in the field of gene editing, Harvard University professor George Church, along with his students Dr. Elizabeth Wood and Dr. Julie Norville, focusing on the development of novel TCR therapies. George Church serves as the chairman of the company's scientific advisory board, Elizabeth Wood as the chief executive officer, and Julie Norville as the company’s chief scientific officer or chief technology officer.

Jura Bio's core research area focuses on the TCR-epitope-HLA synapse, a critical biological target. The TCR-epitope-HLA synapse is an immunological structure formed by the binding of T-cell receptors (TCR) to specific antigen epitopes on major histocompatibility complex (MHC, known as HLA in humans) molecules. It plays a key role in T-cell recognition and response to foreign or abnormal cells. Activation of this synapse is central to triggering T-cell-mediated immune responses, involving cytotoxic T-cell killing activity and helper T-cell immune regulation, and is crucial for the development of personalized medicine and immunotherapy strategies.

At the same time, TCR-epitope-HLA synapses play a crucial role in autoimmune diseases, as these synapses may lead to the abnormal activation of autoreactive T cells, which mistakenly identify the body's normal tissues as foreign threats and launch attacks. This abnormal immune response disrupts immune tolerance and may trigger and exacerbate chronic inflammation, leading to disease progression. Moreover, the presence of these synapses provides targets for the development of new therapeutic strategies, and by modulating or inhibiting these specific immune activation points, it may be possible to potentially alleviate or treat autoimmune diseases.

Moreover, the differences in TCR repertoires and HLA types among individuals lead to varied responses to self-antigens, explaining the personalized disease course of autoimmune disorders. In certain cases, such as infections or cellular stress, the generation of altered epitopes may trigger additional autoimmune reactions. Therefore, an in-depth understanding of the mechanisms underlying the TCR-epitope-HLA synapse is crucial for developing personalized immune-modulating therapies, aiding in designing treatment strategies tailored to specific patient conditions, thereby enhancing therapeutic efficacy and minimizing unnecessary side effects.

This is also one of the goals of Jura Bio's establishment.

During the founding of Jura Bio, Elizabeth Wood and Julie Norville jointly conceived a vision during their postdoctoral research:Create a drug development company based on applying breakthrough achievements in cancer treatment to autoimmune diseases.Over the past seven years of relentless efforts, these two scientists have integrated their profound knowledge in the fields of artificial intelligence and synthetic biology, dedicating themselves to an in-depth study of the mechanisms behind T-cell receptor (TCR) and antigen binding. They have successfully built a comprehensive discovery and development platform aimed at developing innovative immune-based therapies.

In order to achieve this goal,Jura Bio has developed an end-to-end generative machine learning and synthetic biology platform, leveraging its technological platform to design, build, and test next-generation protein-based therapies at scale. The platform system can associate any specific antigen or HLA molecule with potential TCR candidates, aiming to identify TCRs that are effective, safe, and possess both regulatory and polyclonal properties.

In September 2023, Jura Bio completed a $16.1 million financing round led by Michael Chambers, John Ballantyne, Fontus Capital, and Josh Elkington. The funds will be used to accelerate the company's mapping of the adaptive immune system.

It is reported that the key to achieving Jura Bio's goal lies in predicting up to 10²⁸The complex interactions of individual molecules, a number that far exceeds the total amount of stars in the universe, make the task both complex and challenging. The core difficulty in achieving this technology lies in how to efficiently manufacture and test TCRs, epitopes, and HLA molecules, which are key steps in uncovering and utilizing the interactions within the TCR-epitope-HLA synapse.

Jura Bio, through its enhanced machine learning (ML) gene synthesis technology, has successfully created a vast library containing 100 billion potential human TCR candidates. This candidate library not only provides abundant resources for the discovery and development of antigen-specific TCRs but has also enabled the company to achieve breakthrough progress in prostate cancer and other neoantigen targets, which were previously unrecorded in key HLA types.

Dr. Cameron Gardner, the company's research director, previously shared a case of target discovery. Jura Bio had received sequences from six melanoma patients who were resistant to MART-1-specific adoptive cell therapy. In response to the challenge, Jura Bio successfully identified 300 candidate sequences using its HLA-matched TCR variant synthetic library and screened out 10 promising candidates for further expansion and engineering modifications. Additionally, the company has constructed peptide and virome-scale antigen libraries, which are crucial for uncovering potential mechanisms of autoimmune diseases, despite these mechanisms largely remaining a mystery.

Dr. George Church, founder and chair of the Scientific Advisory Board at Jura Bio, emphasized the powerful potential of combining AI-ML with multiplex libraries. He noted that the integration of these two technologies not only works effectively individually but also generates significant synergistic effects, known as ML-ML variational synthesis, which could produce billions to trillions of potential candidates. Dr. Church believes that Jura Bio’s expertise in TCR, MHC, and T-cell engineering places the company at the forefront of technology, with substantial market demand, marking its leading position in personalized medicine and cell therapy.

After completing a new round of financing,Jura Bio has also partnered with Syena, a subsidiary of Replay, to jointly develop TCR therapies by applying artificial intelligence, machine learning, and JURA's TCR discovery platform.According to the agreement, Jura Bio will receive an upfront payment and research funding during the collaboration period. If the option is exercised, Replay and its cell therapy company Syena will be responsible for global development and will hold exclusive global commercialization rights to all TCR-NK therapies generated from the collaboration. Jura Bio will be eligible to receive development, regulatory, and commercial milestone payments.

Elizabeth Wood stated, "The human immune system is a powerful source of safe and effective immune receptors. While one patient may lack the TCR needed to fight cancer, another patient may possess it. By leveraging machine learning to rewrite the gene synthesis process from scratch, we can generate high-quality immune receptor libraries to discover and train probabilistic machine learning models, ensuring a faster development process and identifying TCRs for the most challenging therapeutic targets."

At this stage, Jura Bio is mapping a biological atlas covering antigen-HLA pairs and T-cell receptors, with plans to use this atlas for the development of TCR-related therapies targeting tumors and autoimmune diseases. They aim to complete the predictive map of TCR-antigen-HLA binding by the end of 2024, during which time they will also integrate their machine learning-based gene synthesis platform into the design and discovery of B-cell receptors.